Skip to main content
Terug
Watch Compare

LENZ Therapeutics, Inc.

Datakwaliteit: 100%
LENZ
Nasdaq Manufacturing Chemicals
€ 9,26
▼ € 0,20 (-2,06%)
Marktkapitalisatie: 290,18 M
Prijs
€ 9,26
Marktkapitalisatie
290,18 M
Dagbereik
€ 9,20 — € 9,56
52-Weeksbereik
€ 8,25 — € 50,40
Volume
300.487
Openen € 9,28
50D / 200D Gem.
€ 12,85
27,98% below
50D / 200D Gem.
€ 26,72
65,36% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -70,00 M
Capital efficient — spends only 4,33% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-41,03%
Boven sectorgemiddelde (-53,41%)
ROIC-35,88%
Net Margin-430,25%
Op. Margin-477,46%

Veiligheid

Debt / Equity
N/A
Current Ratio12,69
Interest CoverageN/A

Waardering

PE (TTM)
-3,53
Onder sectorgemiddelde (-1,48)
P/B Ratio1,50
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -3,5 -1,5
P/B 1,5 1,6
ROE % -41,0 -53,4
Net Margin % -430,3 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0,81% weight
PILL logo PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF
0,56% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,06% weight
WSGE logo WSGE Warren Street Global Equity ETF
0,03% weight
MXMTX MXMTX
0,01% weight
ISCB logo ISCB iShares Morningstar Small-Cap ETF
0,01% weight
IWV logo IWV iShares Russell 3000 ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 19,09 M Net Income (TTM) -82,13 M
ROE -41,03% ROA -38,37%
Gross Margin N/A Operating Margin -477,46%
Net Margin -430,25% Free Cash Flow (TTM) -70,00 M
ROIC -35,88% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 12,69
Interest Coverage N/A Asset Turnover 0,09
Working Capital 190,68 M Tangible Book Value 193,93 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,53 Forward P/E N/A
P/B Ratio 1,50 P/S Ratio 15,20
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24,12%
Market Cap 290,18 M Enterprise Value 264,79 M
Per Share
EPS (Diluted TTM) -2,85 Revenue / Share 0,61
FCF / Share -2,23 OCF / Share -2,21
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 4,33% FCF Conversion 85,23%
SBC-Adj. FCF -81,06 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 19,09 M — — — —
Net Income -82,13 M -49,77 M -124,65 M -101,05 M -70,76 M
EPS (Diluted) -2,85 -2,34 -2,19 -1,84 —
Gross Profit — — — — —
Operating Income -91,14 M -58,61 M -135,19 M -105,64 M -60,44 M
EBITDA — — — — —
R&D Expenses 18,67 M 29,80 M 32,14 M 72,79 M 37,93 M
SG&A Expenses 91,14 M 28,81 M — — —
D&A 287.000,0 58.000,0 2,41 M 2,35 M 734.000,0
Interest Expense — — — — —
Income Tax 502.000,0 1.000,0 — 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 305,88 M 215,30 M 188,46 M 321,90 M 401,99 M
Total Liabilities 21,54 M 11,22 M 4,87 M 25,61 M 17,94 M
Shareholders' Equity 284,34 M 204,08 M 183,58 M 296,29 M 384,05 M
Total Debt — — — — —
Cash & Equivalents 25,18 M 20,16 M 184,26 M 47,73 M 376,98 M
Current Assets 301,41 M 211,92 M 188,02 M 275,37 M 381,74 M
Current Liabilities 21,19 M 10,41 M 4,80 M 13,04 M 12,14 M